Literature DB >> 26458607

Vemurafenib-related sterile scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma mimicking distant metastasis.

Jennifer Gibbons Marsico1, Regulo Rodriguez, Joachim Müller, Markus Jörger.   

Abstract

BACKGROUND: Vemurafenib is a selective BRAF-inhibitor that has been approved for the use in patients with advanced BRAF-mutant melanoma. Major adverse events include skin rash, photosensitivity, pruritus, cutaneous squamous-cell carcinoma or keratoacanthoma. OBSERVATION: We present the case of a patient experiencing extensive sterile abscess of the scrotum after nine months of treatment with vemurafenib for oligometastatic (liver) BRAF-mutant melanoma. The scrotal lesion mimicked distant metastasis in a first round of clinical and radiological examinations, but was identified as sterile abscess after surgical exploration and complete excision. The patient went on to receive hemihepatectomy for melanoma supposedly confined to the liver, and continues receiving vemurafenib.
CONCLUSIONS: We describe a remarkable case of probably vemurafenib-related sterile abscess. This adverse event is of substantial clinical relevance, as it mimicks metastatic melanoma and requires careful diagnostic evaluation and proper treatment to allow a favorable patient outcome.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26458607     DOI: 10.4103/0973-1482.136039

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  1 in total

1.  Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion.

Authors:  Judit Kocsis; Anita Árokszállási; Csilla András; Ingrid Balogh; Edit Béres; Júlia Déri; István Peták; Levente Jánváry; Zsolt Horváth
Journal:  J Gastrointest Oncol       Date:  2017-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.